Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 1421430, 8 pages
http://dx.doi.org/10.1155/2016/1421430
Research Article

Metformin Alleviated Aβ-Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons

1Department of Endocrinology and Metabolism, General Hospital of Beijing Military Region, Beijing 100700, China
2Affiliated Hospital of Beijing Institute of Aeronautical Material, Beijing 100060, China
3Department of Neurobiology and Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China

Received 14 March 2016; Revised 21 May 2016; Accepted 25 May 2016

Academic Editor: Amit K. Srivastava

Copyright © 2016 Bin Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Moon, S.-T. Lee, I. G. Kong et al., “Early diagnosis of Alzheimer's disease from elevated olfactory mucosal miR-206 level,” Scientific Reports, vol. 6, article 20364, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto, “Alzheimer's disease: clinical trials and drug development,” The Lancet Neurology, vol. 9, no. 7, pp. 702–716, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Li, X. Wang, Y. Li et al., “Abnormal resting-state functional connectivity strength in mild cognitive impairment and its conversion to Alzheimer's disease,” Neural Plasticity, vol. 2016, Article ID 4680972, 12 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. H. W. Querfurth and F. M. LaFerla, “Alzheimer's disease,” The New England Journal of Medicine, vol. 362, no. 4, pp. 329–344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. X. Li, D. Song, and S. X. Leng, “Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment,” Clinical Interventions in Aging, vol. 10, pp. 549–560, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. D. D. Buss, “The legacy of Dr. Alzheimer. Nearly a century after the disease got its name, the spotlight on care burns brighter than ever,” Contemporary Longterm Care, vol. 17, no. 2, pp. 42–46, 1994. View at Google Scholar · View at Scopus
  7. P. I. Moreira, K. Honda, X. Zhu et al., “Brain and brawn: parallels in oxidative strength,” Neurology, vol. 66, no. 2, pp. S97–S101, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. D. J. Selkoe, “Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein,” Journal of Alzheimer's Disease, vol. 3, no. 1, pp. 75–80, 2001. View at Google Scholar · View at Scopus
  9. K. Gudala, D. Bansal, F. Schifano, and A. Bhansali, “Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies,” Journal of Diabetes Investigation, vol. 4, no. 6, pp. 640–650, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Luchsinger, C. Reitz, L. S. Honig, M.-X. Tang, S. Shea, and R. Mayeux, “Aggregation of vascular risk factors and risk of incident Alzheimer disease,” Neurology, vol. 65, no. 4, pp. 545–551, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Ott, R. P. Stolk, F. Van Harskamp, H. A. P. Pols, A. Hofman, and M. M. B. Breteler, “Diabetes mellitus and the risk of dementia: The Rotterdam Study,” Neurology, vol. 53, no. 9, pp. 1937–1942, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. D. M. Nathan, J. B. Buse, M. B. Davidson et al., “Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy,” Diabetes Care, vol. 32, no. 1, pp. 193–203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Patel, X. Zhang, N. A. Tautiva et al., “Small molecules and Alzheimer’s disease: misfolding, metabolism and imaging,” Current Alzheimer Research, vol. 12, no. 5, pp. 445–461, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. M. Hettich, F. Matthes, D. P. Ryan et al., “The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex,” PLoS ONE, vol. 9, no. 7, Article ID e102420, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Picone, D. Nuzzo, L. Caruana et al., “Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-κB activation: use of insulin to attenuate metformin's effect,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1853, no. 5, pp. 1046–1059, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Xing, Y. Yin, R. Chang, X. He, and Z. Xie, “A role of insulin-like growth factor 1 in β amyloid-induced disinhibition of hippocampal neurons,” Neuroscience Letters, vol. 384, no. 1-2, pp. 93–97, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Fang, T. Su, X. Qiu et al., “Protective effect of α-mangostin against oxidative stress induced-retinal cell death,” Scientific Reports, vol. 6, Article ID 21018, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Cui, M. Zhang, Y.-Q. Zhang, and Z.-H. Xu, “JNK pathway: diseases and therapeutic potential,” Acta Pharmacologica Sinica, vol. 28, no. 5, pp. 601–608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Yarza, S. Vela, M. Solas, and M. J. Ramirez, “c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer’s disease,” Frontiers in Pharmacology, vol. 6, article 321, 2016. View at Publisher · View at Google Scholar
  20. X. Zhu, A. K. Raina, C. A. Rottkamp et al., “Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease,” Journal of Neurochemistry, vol. 76, no. 2, pp. 435–441, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Killick, E. M. Ribe, R. Al-Shawi et al., “Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway,” Molecular Psychiatry, vol. 19, no. 1, pp. 88–98, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Gourmaud, C. Paquet, J. Dumurgier et al., “Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline,” Journal of Psychiatry and Neuroscience, vol. 40, no. 3, pp. 151–161, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. A. D. Cohen and W. E. Klunk, “Early detection of Alzheimer's disease using PiB and FDG PET,” Neurobiology of Disease, vol. 72, pp. 117–122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Yarchoan, J. B. Toledo, E. B. Lee et al., “Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies,” Acta Neuropathologica, vol. 128, no. 5, pp. 679–689, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Barini, O. Antico, Y. Zhao et al., “Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy,” Molecular Neurodegeneration, vol. 11, article 16, 2016. View at Publisher · View at Google Scholar
  26. F. Chen, R. R. Dong, K. L. Zhong et al., “Antidiabetic drugs restore abnormal transport of amyloid-β across the blood-brain barrier and memory impairment in db/db mice,” Neuropharmacology, vol. 101, pp. 123–136, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Chen, K. Zhou, R. Wang et al., “Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 10, pp. 3907–3912, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Bamji-Mirza, D. Callaghan, D. Najem et al., “Stimulation of insulin signaling and inhibition of JNK-AP1 activation protect cells from amyloid-β-induced signaling dysregulation and inflammatory response,” Journal of Alzheimer's Disease, vol. 40, no. 1, pp. 105–122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Yenki, F. Khodagholi, and F. Shaerzadeh, “Inhibition of phosphorylation of JNK suppresses Aβ-induced ER stress and upregulates prosurvival mitochondrial proteins in rat hippocampus,” Journal of Molecular Neuroscience, vol. 49, no. 2, pp. 262–269, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Mohammadi, J. Guan, F. Khodagholi et al., “Reduction of autophagy markers mediated protective effects of JNK inhibitor and bucladesine on memory deficit induced by Aβ in rats,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 389, no. 5, pp. 501–510, 2016. View at Google Scholar · View at Scopus
  31. C. Paquet, J. Dumurgier, and J. Hugon, “Pro-apoptotic kinase levels in cerebrospinal fluid as potential future biomarkers in Alzheimer's disease,” Frontiers in Neurology, vol. 6, article 168, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Triaca, V. Sposato, G. Bolasco et al., “NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer's disease,” Aging Cell, 2016. View at Publisher · View at Google Scholar
  33. S. Lagalwar, A. L. Guillozet-Bongaarts, R. W. Berry, and L. I. Binder, “Formation of phospho-SAPK/JNK granules in the hippocampus is an early event in Alzheimer disease,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 5, pp. 455–464, 2006. View at Publisher · View at Google Scholar · View at Scopus